Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Research
| Technology Name (St. Jude Reference #) | Human Multidrug Resistance Protein 4 (MRP4) (SJ-98-0013) |
| Description | The human multidrug resistance protein 4 (MRP4), a member of the ATP-binding cassette (ABC) transporter superfamily is involved in the efflux of antiretroviral drugs such as PMEA and AZT, drugs used in the treatment of HIV infections. MRP4 overexpression causes increased efflux of such drugs from the cell allowing the growth of HIV. MRP4 expression could also affect the efficacy of nucleoside analogs used to treat other diseases such as herpesvirus infections, hepatitis B virus infections, and cancer. The MRP4 technology could be used by the pharmaceutical industry to identify patients who are resistant and those who are likely to develop resistance to antiretroviral drug therapy, as well as for other applications relating to drug development. |
| Keywords | Drug resistance, transporter, HIV, cancer, drug development |
| Granted Patents or Published Applications | U.S. Patent No. 6,759,238 |
| Related Scientific References | Schuetz, John D., et al. "MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs" Nature Medicine 5:1048-1051 (1999). |
| Licensing Opportunities | We are currently seeking licensing opportunities in all fields for the development of this technology. |
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.
Last update: June 2005
